Koshinski Asset Management Inc. Makes New $396,000 Investment in Edwards Lifesciences Co. (NYSE:EW)

Koshinski Asset Management Inc. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 6,000 shares of the medical research company’s stock, valued at approximately $396,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in shares of Edwards Lifesciences by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 52,964,394 shares of the medical research company’s stock worth $5,061,277,000 after acquiring an additional 600,994 shares during the period. Bank of New York Mellon Corp grew its holdings in Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after purchasing an additional 809,605 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock valued at $622,695,000 after buying an additional 2,390,137 shares in the last quarter. Champlain Investment Partners LLC raised its stake in shares of Edwards Lifesciences by 3.1% during the 1st quarter. Champlain Investment Partners LLC now owns 2,964,168 shares of the medical research company’s stock worth $283,256,000 after buying an additional 88,205 shares during the last quarter. Finally, AustralianSuper Pty Ltd boosted its position in shares of Edwards Lifesciences by 14.2% in the 2nd quarter. AustralianSuper Pty Ltd now owns 2,778,812 shares of the medical research company’s stock worth $256,679,000 after buying an additional 344,465 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 16,250 shares of company stock worth $1,099,238. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Barclays cut their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. UBS Group dropped their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Tuesday, September 10th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Finally, The Goldman Sachs Group cut their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Seventeen equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $75.77.

Edwards Lifesciences Stock Down 1.0 %

Shares of NYSE:EW opened at $68.90 on Wednesday. The stock has a 50-day simple moving average of $67.45 and a 200-day simple moving average of $79.60. The stock has a market capitalization of $41.52 billion, a P/E ratio of 29.70, a PEG ratio of 2.83 and a beta of 1.13. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the firm earned $0.66 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 6.7% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.